The Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index includes over 130 component companies), while the Dow Jones Biotech Index declined 3% (which includes 33 companies).
As a follow-up to my recent article on nine extreme FDA trades of pending new product decisions among small and micro-cap companies, I have examined the BioMedReports.com Clinical Trial Calendar database to find companies with market caps below $250M which have pending Phase 2 or 3 clinical trial results expected before the end of 2009.
Below is a sample of 10 stocks meeting this criteria from the database of 111 entries included in the BioMedReports.com Clinical Trial Calendar, which is in addition to the 120 entries in the FDA Calendar database as of 5/13/09.
Recently, we sat down with Zacks senior biotechnology industry analyst Grant Zeng, CFA to discuss his outlook on this group ahead of first quarter earnings.
What is your outlook for the biotech group overall at this time?
Recently, we sat down with Zacks senior biotechnology industry analyst Grant Zeng, CFA to discuss fourth-quarter earnings season among his group, and where he expects the industry to be headed throughout 2008.
Now that most biotech companies have reported earnings, has your outlook for fiscal year 2008 changed at all?
Alan Brochstein, CFA submits:
After plunging in the weeks following ASCO, cancer stocks were stabilized this week.
The lists below, with data from StockVal, are comprised of domestic companies primarily with market caps in excess of $50mm, ranked by the return this past week.
There were much fewer outliers this week, with 5 double-digit gainers and just three double-digit decliners. The median return of -0.7% trailed the S&P 500 return, which was flat, but the average of 0.1% was in...
Alan Brochstein, CFA submits:
After plunging in the week following ASCO and then underperforming the following week, cancer stocks were hammered yet again.
The list below, with data from StockVal, is comprised of domestic companies primarily with market caps in excess of $50mm, ranked by the return this past week.
The 14 double-digit declines exceeded the 12 that plunged immediately following the ASCO meeting, with just a single double-digit gainer. The median return of -4.2% and the average...
Alan Brochstein, CFA submits:
After plunging in the week following ASCO, cancer-related stocks merely underperformed this week.
The list below, with data from StockVal, is comprised of domestic companies primarily with market caps in excess of $50mm, ranked by the return this past week.
The number of double-digit declines decreased from 12 to just 4, but there were no double-digit gainers. The median return of 0.0 and the average return of -0.3 trailed the S&P 500 significantly (-1.6% and -2%...
Alan Brochstein, CFA submits:
Cancer-related stocks soared during the holiday-shortened week as presentations began on June 1st at the ASCO annual meeting in Chicago.
Last week?s big winner, Bioenvision (BIVN), received an offer from partner Genzyme (GENZ) at a disappointing premium but well ahead of multi-year lows reached in early May.
The list below is comprised of domestic companies primarily with market caps in excess of $50mm, ranked...
Alan Brochstein, CFA submits:
Later this week, the big event of the year for companies trying to treat cancer takes place in Chicago: the American Society of Clinical Oncology?s Annual Meeting. Not surprisingly, the universe of cancer stocks performed well in a rather lackluster week for the market.
I recently created a list of companies with market capitalization in excess of $50mm at the beginning of May that derive a significant amount of their market value from cancer-related pursuits. ...
Point Roberts, WA (Investorideas.com Newswire) August 16, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($2.00-$5.00) include Voyager Oil ...
Genta, a biopharmaceutical company, has reported that net income for the second quarter ended June 30, 2010 was $25.44 million, or $0.42 per diluted share, compared to a net loss of $43.08 million ...
Point Roberts, WA (Investorideas.com Newswire) August 13, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($2.00-$5.00) include Genta ...
By Ekaterina Zelenkova Today, investors of Genta Incorporated (OTC:GETAD) stock may experience the feeling of having done a really valuable investment this time. After the 1:100 reverse stock ...
Liquidmetal Technologies, Inc. (PINK:LQMT), Genta Incorporated (OTC:GETAD) and MOP Environmental Solutions, Inc. (PINK:MOPN) are three small stocks with big moves during today's session ...
BERKELEY HEIGHTS, NJ, Aug 12, 2010 (BUSINESS WIRE) -- Genta Incorporated (OTCBB: GETAD.OB) today announced financial results for the quarter ending June 30, 2010. Corporate highlights for the ...
Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions. On 08/05/10, Exelixis, Inc. (Nasdaq:EXEL) reported financial results for the ...
For full details on (GETAD) GETAD. (GETAD) has Short Term PowerRatings at TradingMarkets. Details on (GETAD) Short Term PowerRatings is available at This Link. Do you want to learn how to trade ...
BERKELEY HEIGHTS, NJ--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GETAD.OB) announced today that the Company will release its second quarter 2010 financial results on Thursday, August 12, 2010 ...
By Justin Kuepper on Wednesday, August 4th, 2010 Bio-Path Holdings Inc. (OTC-BB: BPTH), which is developing a novel cancer treatment, alongside companies like Genta Incorporated (OTC-BB: GETA) and ...
Stock News 
